Human Natural Killer Cell Biology

Molecular Medicine Program

Department of Medicine and Life Sciences

PRBB building (Mar campus)
Doctor Aiguader, 88
08003 Barcelona

 +34 93 316 0859/0822

[email protected]

CV sketch -  Orcid  


Funding (last 5 years):

  • Natural killer cell-based anti-cancer Immunotherapies. NATURIMMUN: Research training in molecular medicine and biotechnology business. (E.Hofer/U. Köhl coordinators) (FP7 Marie Sklodowska Curie Training Network; FP7-PEOPLE-2012-ITN-3170132013-2016). PI: M. López-Botet (UPF)
  • Evaluation of NK cell contribution to chronic kidney allograft rejection in response to HLA-specific alloantibodies, genetic mismatch and CMV infection. (M. Crespo, coordinator). La Marató TV3 Foundation (137/C/2012; 2013-2015). Univ. Pompeu Fabra. PI M. López-Botet (UPF)
  • Analysis of the human NK-cell receptor repertoire and its adaptive reconfiguration by HCMV infection: mechanisms and implications in immunity. Programa Estatal I+D Retos, Ministry of Economy and Competitiveness (SAF2013-49063-C2-1-R; 2014-2016). PI: M. López-Botet (UPF)
  • Development of molecular tools to enhance NK cell-mediated ADCC responses elicited by trastuzumab against breast cancer (M. López-Botet, coordinator). Worldwide Cancer Research (Formerly AICR, 15-1146) (2015-2018). PIs: M. López-Botet and A. Muntasell (IMIM)
  • Spanish Multiple Sclerosis Network (REEM), (Instituto de Salud Carlos III; 2013-). Co-PI J.E. Martínez. PIs: M. López-Botet and J.E. Martínez (IMIM)
  • Targeting Natural Killer cells against cytomegalovirus (TANKACY; H. Hengel coordinator). EU-Ministry of Economy and Competitiveness. Infect ERA program. (PCIN-2015-191-C02-01; 2015-2018). PI: M. López-Botet (IMIM)
  • Potenciación de la citotoxicidad dependiente de anticuerpo mediada por linfocitos NK para la inmunoterapia del cáncer (I. Melero, coordinator). Fundación Científica Asociación Española contra el Cáncer (AECC GCB15152947MELE; 2015-2019). PIs: M. López-Botet and A. Muntasell (UPF)
  • Uncovering resistance to monoclonal antibodies in colorectal and breast cancer. (J. Albanell coordinator). Proyecto Integrado de Excelencia ISCIII (PIE 2015/00008, 2015-2019).  PIs: M. López-Botet and A. Muntasell (IMIM)
  • Molecular basis of the adaptive NK cell response to human cytomegalovirus: role of viral factors. (M. López-Botet, coordinator). Programa Estatal I+D Retos, Ministry of Economy and Competitiveness (SAF2016-80363-C2-1-R; 2017-2019). PI: M. López-Botet (UPF)
  • Manufacturing tumor-reactive Natural Killer cells (MATURE-NK). Coordinator: Ulrike Köhl (Hannover) EC Horizon 2020. Marie Sklodowska Curie-Innovative Training Network No. 765104 (2019-2021). PIs: M. López-Botet and A. Muntasell (UPF)
  • Adaptive NK cell-mediated response to cytomegalovirus in the context of immunosuppression: clinical implications in renal transplantation. Fundació La Marató de TV3 (P 105/U/2018) (2019-2021). M. López-Botet (IMIM)
  • NK cell and TGFβ crosstalk in colorectal cancer: from biomarkers to immunotherapy. Proyectos de Investigación en Salud (AES2019). Ministerio de Ciencia, Innovación y Universidades. (Ref. PI19/00328, 2020-2022). PI: Aura Muntasell (IMIM)